Thus, new therapeutic strategies to either activate TNFR2 signalling in ACR (to facilitate tubular regeneration) or to selectively inhibit TNFR2 signalling in ccRCC (to halt tumor growth/progression) may be a better approach in the treatment of these conditions than global blockade of TNF. Here, TNFRSF1B is linked to nonpapillary renal cell carcinoma.